Robb J. Muirhead,Adina I. Soaita
Abstract:This paper explores an approach to Bayesian sample size determination in clinical trials. The approach falls into the category of what is often called "proper Bayesian", in that it does not mix frequentist concepts with Bayesian ones. A criterion for a "successful trial" is defined in terms of a posterior probability, its probability is assessed using the marginal distribution of the data, and this probability forms the basis for choosing sample sizes. We illustrate with a standard problem in clinical trials, that of establishing superiority of a new drug over a control.
What problem does this paper attempt to address?
The problem that this paper attempts to solve is how to use the Bayesian method to determine the sample size in clinical trials. Specifically, the author proposes a "proper Bayesian" method to determine the sample size. This method does not mix the concepts of the frequentist school with Bayesian concepts. Instead, it defines the criteria for a successful trial based on the posterior probability and evaluates this probability through the marginal distribution of the data, thereby selecting an appropriate sample size.
### Main problems:
1. **Importance of sample size determination**: In research design in many fields, especially in the planning of clinical trials, sample size determination plays an important role. Although traditional frequentist methods are widely used, they have some limitations. For example, the estimation of unknown parameters may underestimate the actual variability, resulting in insufficient trial power.
2. **Advantages of the Bayesian method**: Due to the uncertainties in specifying the effect size and nuisance parameters in the frequentist method, the Bayesian concept is naturally introduced. The Bayesian method can incorporate prior knowledge through the prior distribution and improve the understanding of the impact on the sample size.
3. **Definition of "successful trial"**: In the paper, a criterion for a successful trial is defined, that is, the posterior probability of the trial is greater than or equal to a certain threshold \(\eta\) (\(\eta\in(0, 1)\)). The choice of this threshold will affect the determination of the sample size.
4. **Probability calculation**: In the design stage, calculate the probability of a successful trial (PST) through the marginal distribution (or unconditional distribution) of the data, and select the sample size that makes PST exceed the preset threshold.
### Specific applications:
- **Comparison of two sets of normally distributed data**: The paper shows through specific examples how to apply this method in clinical trials comparing the means of two normally distributed samples. These examples include cases with known precision and conjugate priors, as well as cases with unknown precision and conjugate priors.
- **Normalized PST index**: In order to better understand the impact of the sample size, the paper proposes a normalized PST index, which represents the proportion of PST at the current sample size to the maximum value.
### Conclusion:
The "proper Bayesian" method proposed in the paper is not only applicable to superiority trials, but can also be extended to the determination of sample sizes in non - inferiority and equivalence trials, as well as for non - normal data (such as binary data and survival data). By introducing the prior distribution, this method can handle uncertainties and prior knowledge more flexibly, thereby improving the rationality of trial design.